‘Restraint’ an Unspoken Watchword of Algae Biomass Sessions

A few basic themes seemed to emerge in the first few presentations yesterday afternoon during the 3rd Annual Algae Biomass Summit.

One theme is that the algae biofuels industry remains at a nascent stage of development, despite widespread enthusiasm over the size of San Diego-based Synthetic Genomics’ deal with ExxonMobil, and venture funding for Sapphire Energy. Biologist Steve Mayfield, a Sapphire co-founder who is moving from The Scripps Research Institute to UC San Diego, says scientific papers published about the E. coli bacteria outnumber the papers published about a common algae strain by nearly 50 to 1. That is a ratio that needs to be reversed, Mayfield says.

Another theme is that some industry leaders have been overly optimistic in saying that algae-based biofuels can be brought to market in two to four years. Bill Barclay of Columbia, MD-based Martek Biosciences says he spent 11 years developing and commercializing methods for using algae to produce a nutritional supplement called Omega-3 DHA (docosahexaenoic acid), an unsaturated fatty acid. (The startup that Barclay founded in 1987, Boulder, CO-based OmegaTech, was acquired by Martek for about $50 million in 2002.)

The process Barclay went through to make nutritional supplements from algae is comparable to the current effort to develop algae-based biofuels. But Barclay, a scientist who oversees Martek’s intellectual property, says much of the fundamental production technology is “immature,” and that timelines of two to four years from inception to production are unrealistic. Barclay says flatly, “Commercially feasible biodiesel from photosynthetic algae is more than 10 years away.”

And finally, the substitute for keynote speaker J. Craig Venter seemed determined not to say anything that Venter, his boss at San Diego’s Synthetic Genomics, had not previously disclosed publicly.

In other words, “restraint” was the unspoken watchword of the first day.

Venter, a pioneer in genetic sequencing and the founding CEO of Synthetic Genomics, already had agreed to be the conference headliner when he learned he had won a National Medal of Science (the highest honor awarded to scientists by the United States government). But later, Venter learned the White House scheduled the award ceremony with

Author: Bruce V. Bigelow

In Memoriam: Our dear friend Bruce V. Bigelow passed away on June 29, 2018. He was the editor of Xconomy San Diego from 2008 to 2018. Read more about his life and work here. Bruce Bigelow joined Xconomy from the business desk of the San Diego Union-Tribune. He was a member of the team of reporters who were awarded the 2006 Pulitzer Prize in National Reporting for uncovering bribes paid to San Diego Republican Rep. Randy “Duke” Cunningham in exchange for special legislation earmarks. He also shared a 2006 award for enterprise reporting from the Society of Business Editors and Writers for “In Harm’s Way,” an article about the extraordinary casualty rate among employees working in Iraq for San Diego’s Titan Corp. He has written extensively about the 2002 corporate accounting scandal at software goliath Peregrine Systems. He also was a Gerald Loeb Award finalist and National Headline Award winner for “The Toymaker,” a 14-part chronicle of a San Diego start-up company. He takes special satisfaction, though, that the series was included in the library for nonfiction narrative journalism at the Nieman Foundation for Journalism at Harvard University. Bigelow graduated from U.C. Berkeley in 1977 with a degree in English Literature and from the Columbia University Graduate School of Journalism in 1979. Before joining the Union-Tribune in 1990, he worked for the Associated Press in Los Angeles and The Kansas City Times.